Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs

Nephrology Dialysis Transplantation

Volumn 25, Issue 2, 2010, Pages 426-433

  Haschke, Manuel ^a   Vitins, Tanja ^a   Lüde, Saskia ^a   Todesco, Liliane ^a   Novakova, Katerina ^a   Herrmann, Richard ^b   Krähenbühl, Stephan ^a  

^a Division of Clinical Pharmacology and Toxicology   (Switzerland)

^b PSI   (Switzerland)

Author keywords

Carboplatin; Carnitine; Cisplatin; OCTN2; Oxaliplatin

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CARNITINE; CISPLATIN; CYTARABINE; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IMMUNOGLOBULIN G; MAGNESIUM; METHOTREXATE; NAVELBINE; ORGANIC CATION TRANSPORTER 2; OXALIPLATIN; PACLITAXEL; PREDNISONE; RITUXIMAB; SEROTONIN 3 ANTAGONIST; TRANSFERRIN;

ADULT; AGED; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; LUNG NON SMALL CELL CANCER; MALE; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OROPHARYNX CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URINARY EXCRETION; URINARY TRACT CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARBOPLATIN; CARNITINE; CELLS, CULTURED; CISPLATIN; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; ORGANOPLATINUM COMPOUNDS;

EID: 75649139495     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp456     Document Type: Article

References (37)

1. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13: 228-244
2. Yao X, Panichpisal K, Kurtzman N et al. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334: 115-124
3. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinet-ics and administration of established platinum drugs. Drugs 2000; 59(Suppl 4): 19-27
4. Simpson D, Dunn C, Curran M et al. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 2003; 63: 2127-2156 (Pubitemid 37229090)
5. Heuberger W, Berardi S, Jacky E et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998; 54: 503-508
6. Mancinelli A, D'Iddio S, Bisonni R et al. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol 2007; 60: 19-26
7. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983; 63: 1420-1480
8. Rebouche CJ, Paulson DJ. Carnitine metabolism and function in humans. Annu Rev Nutr 1986; 6: 41-66
9. Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. Biochem J 2002; 361: 417-429
10. Krahenbuhl S. Carnitine metabolism in chronic liver disease. Life Sci 1996; 59: 1579-1599
11. Nezu J, Tamai I, Oku A et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999; 21: 91-94
12. Stieger B, O'Neill B, Krahenbuhl S. Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. Biochem J 1995; 309 (Pt 2): 643-647
13. Tamai I, Ohashi R, Nezu J et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998; 273: 20378-20382
14. Ganapathy ME, Huang W, Rajan DP et al. beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 2000; 275: 1699-1707
15. Ohashi R, Tamai I, Yabuuchi H et al. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 1999; 291: 778-784
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
17. Todesco L, Bur D, Brooks H et al. Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2. Cell Mol Life Sci 2008; 65: 1596-1608
18. Cederblad G, Lindstedt S. A method for the determination of carnitine in the picomole range. Clin Chim Acta 1972; 37: 235-243
19. Brass EP, Hoppel CL. Carnitine metabolism in the fasting rat. J Biol Chem 1978; 253: 2688-2693
20. Regeniter A, Siede WH, Scholer A et al. Interpreting complex urinary patterns with MDI LABLINK: a statistical evaluation. Clin Chim Acta 2000; 297: 261-273
21. Millward MJ, Zalcberg J, Bishop JF et al. Phase I trial of do-cetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 750-758
22. Miller SE, House DA. The hydrolysis products of cis- dichlorodiammineplatinum(II) 3. Hydrolysis kinetics at physiological pH. Inorganica Chimica Acta 1990; 173: 53-60
23. Wang D,Lippard SJ. Cellular processingofplatinum anticancerdrugs. Nat Rev Drug Discov 2005; 4: 307-320
24. Jacobs SS, Fox E, Dennie C et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carbo-platin in nonhuman primates. Clin Cancer Res 2005; 11: 1669-1674
25. Dodson WL, Sachan DS, Krauss S et al. Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr 1989; 8: 133-142
26. Rebouche CJ, Lombard KA, Chenard CA. Renal adaptation to dietary carnitine in humans. Am J Clin Nutr 1993; 58: 660-665
27. D'Amico G, Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 2003; 12: 639-643
28. Herget-Rosenthal S, Poppen D, Husing J et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50: 552-558
29. Vickers AE, Rose K, Fisher R et al. Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 2004; 32: 577-590
30. Tanaka H, Ishikawa E, Teshima S et al. Histopathological study of human cisplatin nephropathy. Toxicol Pathol 1986; 14: 247-257
31. Yonezawa A, Masuda S, Yokoo S et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006; 319: 879-886
32. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001; 280: F562-F573
33. Klassen RB, Crenshaw K, Kozyraki R et al. Megalin mediates renal uptake of heavy metal metallothionein complexes. Am J Physiol Renal Physiol 2004; 287: F393-F403
34. Portilla D, Dai G, McClure T et al. Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 2002; 62: 1208-1218
35. Kim MS, Sweeney TR, Shigenaga JK et al. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRal-pha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism 2007; 56: 267-279
36. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-842
37. van Vlies N, Ferdinandusse S, Turkenburg M et al. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochim Biophys Acta2007; 1767: 1134-1142